BRPI1010772A2 - composto,e, composição farmacêutica. - Google Patents
composto,e, composição farmacêutica.Info
- Publication number
- BRPI1010772A2 BRPI1010772A2 BRPI1010772A BRPI1010772A BRPI1010772A2 BR PI1010772 A2 BRPI1010772 A2 BR PI1010772A2 BR PI1010772 A BRPI1010772 A BR PI1010772A BR PI1010772 A BRPI1010772 A BR PI1010772A BR PI1010772 A2 BRPI1010772 A2 BR PI1010772A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09162630.9 | 2009-06-12 | ||
| EP09162630A EP2261214A1 (en) | 2009-06-12 | 2009-06-12 | Compounds useful to treat premature aging and in particular progeria |
| EP09305540.8 | 2009-06-12 | ||
| EP20090305540 EP2266972A1 (en) | 2009-06-12 | 2009-06-12 | New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies |
| PCT/IB2010/052651 WO2010143169A2 (en) | 2009-06-12 | 2010-06-14 | Compounds useful for treating aids |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI1010772A2 true BRPI1010772A2 (pt) | 2016-11-01 |
| BRPI1010772B1 BRPI1010772B1 (pt) | 2020-10-27 |
| BRPI1010772B8 BRPI1010772B8 (pt) | 2021-05-25 |
Family
ID=43309298
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1010772A BRPI1010772B8 (pt) | 2009-06-12 | 2010-06-14 | compostos de quinolina, suas composições farmacêuticas e seus usos para tratar aids |
| BRPI1012892A BRPI1012892B8 (pt) | 2009-06-12 | 2010-06-14 | compostos de fórmula (i), como tal, composição farmacêutica que os compreende e seu uso no tratamento de hgps, progeria, desordem de charcot-marie-tooth, síndrome de werner, diabetes, osteoporose e envelhecimento da pele |
| BRPI1010768A BRPI1010768C8 (pt) | 2009-06-12 | 2010-06-14 | composto de fórmula (i) |
| BR122019013686-6A BR122019013686B1 (pt) | 2009-06-12 | 2010-06-14 | Composto de fórmula (i), composto de fórmula (iq) e composição farmacêutica |
| BR122019013687A BR122019013687B1 (pt) | 2009-06-12 | 2010-06-14 | composto de fórmula (i) |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1012892A BRPI1012892B8 (pt) | 2009-06-12 | 2010-06-14 | compostos de fórmula (i), como tal, composição farmacêutica que os compreende e seu uso no tratamento de hgps, progeria, desordem de charcot-marie-tooth, síndrome de werner, diabetes, osteoporose e envelhecimento da pele |
| BRPI1010768A BRPI1010768C8 (pt) | 2009-06-12 | 2010-06-14 | composto de fórmula (i) |
| BR122019013686-6A BR122019013686B1 (pt) | 2009-06-12 | 2010-06-14 | Composto de fórmula (i), composto de fórmula (iq) e composição farmacêutica |
| BR122019013687A BR122019013687B1 (pt) | 2009-06-12 | 2010-06-14 | composto de fórmula (i) |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US9145367B2 (pt) |
| EP (6) | EP3521283B1 (pt) |
| JP (8) | JP5905385B2 (pt) |
| KR (14) | KR101863021B1 (pt) |
| CN (13) | CN103948594B (pt) |
| AU (3) | AU2010258295B2 (pt) |
| BR (5) | BRPI1010772B8 (pt) |
| CA (5) | CA2764026C (pt) |
| CU (4) | CU24124B1 (pt) |
| DK (3) | DK2440546T3 (pt) |
| ES (3) | ES2736198T3 (pt) |
| FI (2) | FI2440546T3 (pt) |
| HK (8) | HK1173153A1 (pt) |
| HR (2) | HRP20230143T1 (pt) |
| HU (2) | HUE045548T2 (pt) |
| LT (1) | LT2440547T (pt) |
| MX (9) | MX359575B (pt) |
| PL (3) | PL2440546T3 (pt) |
| PT (3) | PT2440546T (pt) |
| RU (1) | RU2567752C2 (pt) |
| SI (1) | SI2440547T1 (pt) |
| TR (1) | TR201910781T4 (pt) |
| WO (3) | WO2010143170A2 (pt) |
| ZA (2) | ZA201109032B (pt) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX359575B (es) * | 2009-06-12 | 2018-10-03 | Abivax | Compuestos utiles para tratar sida. |
| US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
| MX2019008390A (es) * | 2009-06-12 | 2019-09-09 | Abivax | Compuestos utiles para tratar cancer. |
| BR112012004533B1 (pt) | 2009-09-03 | 2021-11-09 | Bioenergenix | Composto, composição farmacêutica, e uso do composto |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| EP2465502A1 (en) | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
| WO2012094462A2 (en) | 2011-01-05 | 2012-07-12 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| US8916561B2 (en) | 2011-03-02 | 2014-12-23 | Bioenergenix, Llc | Substituted quinoxaline compounds for the inhibition of PASK |
| US8912188B2 (en) | 2011-03-02 | 2014-12-16 | Bioenergenix, Llc | Substituted quinoxaline carboxylic acids for the inhibition of PASK |
| GB201118652D0 (en) * | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| FR2987627B1 (fr) | 2012-03-05 | 2016-03-18 | Splicos | Utilisation de rbm39 comme biomarqueur |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| IN2014DN11205A (pt) | 2012-06-20 | 2015-10-02 | Eutropics Pharmaceuticals Inc | |
| TW201410657A (zh) | 2012-08-02 | 2014-03-16 | Endo Pharmaceuticals Inc | 經取代胺基－嘧啶衍生物 |
| EP2882722B1 (en) | 2012-08-13 | 2016-07-27 | Takeda Pharmaceutical Company Limited | Quinoxaline derivatives as gpr6 modulators |
| JP2014237624A (ja) * | 2012-10-23 | 2014-12-18 | 日本曹達株式会社 | ピリジン化合物またはその塩、有害生物防除剤、殺虫剤または殺ダニ剤、および外部寄生虫防除剤 |
| EP2922544B1 (en) | 2012-11-21 | 2018-08-01 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
| GB201301571D0 (en) * | 2012-11-27 | 2013-03-13 | Fundanci N Pedro Barri De La Maza | Product and use |
| US20140194465A1 (en) * | 2013-01-04 | 2014-07-10 | Novarx Corporation | Compositions for treatment of cancer |
| EP2757161A1 (en) * | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| CA2916623C (en) | 2013-07-05 | 2021-09-14 | Abivax | Bicyclic compounds useful for treating diseases caused by retroviruses |
| WO2015005491A1 (ja) | 2013-07-12 | 2015-01-15 | 国立大学法人京都大学 | 疾病の発症又は進行の一因となる異常スプライシングを抑制できる物質のスクリーニング方法 |
| US10732182B2 (en) | 2013-08-01 | 2020-08-04 | Eutropics Pharmaceuticals, Inc. | Method for predicting cancer sensitivity |
| WO2015066305A1 (en) | 2013-10-30 | 2015-05-07 | Eutropics Pharmaceuticals, Inc. | Methods for determining chemosensitivity and chemotoxicity |
| JO3466B1 (ar) | 2013-12-20 | 2020-07-05 | Takeda Pharmaceuticals Co | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 |
| JP6526034B2 (ja) | 2014-02-14 | 2019-06-05 | 武田薬品工業株式会社 | Ｇｐｒ６のピリドピラジンモジュレーター |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| EP3122358B1 (en) | 2014-03-26 | 2020-12-16 | Astex Therapeutics Ltd. | Combinations of fgfr- and cmet-inhibitors for the treatment of cancer |
| AU2015238305B2 (en) | 2014-03-26 | 2020-06-18 | Astex Therapeutics Ltd | Combinations of an FGFR inhibitor and an IGF1R inhibitor |
| EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| EP2975034A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | A quinoline derivative for the treatment of inflammatory diseases and AIDS |
| BR112017015204A8 (pt) | 2015-01-30 | 2021-02-23 | Centre Nat Rech Scient | isoformas de delta133p53beta e delta133p53gama são biomarcadores de células tronco de câncer |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| EP3059591A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | Methods for screening compounds for treating or preventing a viral infection or a virus-related condition |
| EP3058940A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of viral infection |
| EP3059236A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | A new quinoline derivative for use in the treatment and prevention of viral infections |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| HRP20220012T1 (hr) | 2015-09-23 | 2022-04-01 | Janssen Pharmaceutica Nv | Bi-heteroaril supstituirani 1,4-benzodiazepini i njihova upotreba za liječenje raka |
| SI3353177T1 (sl) | 2015-09-23 | 2020-08-31 | Janssen Pharmaceutica Nv | Triciklični heterocikli za zdravljenje raka |
| US11129824B2 (en) | 2015-12-17 | 2021-09-28 | Biokine Therapeutics Ltd. | Small molecules for inhibiting chemokine activity and/or cancer cells growth |
| US10646465B2 (en) | 2015-12-17 | 2020-05-12 | Biokine Therapeutics Ltd. | Small molecules against cancer |
| JP6966456B2 (ja) * | 2016-02-03 | 2021-11-17 | ヤンセン ファーマシューティカ エヌ．ベー． | タウｐｅｔ画像化リガンド |
| ES2899926T3 (es) * | 2016-03-18 | 2022-03-15 | Prosynergia S A R L | Procedimiento para preparar derivados de quinolin-2-il-fenilamina y sus sales |
| ES2846833T3 (es) * | 2016-07-18 | 2021-07-29 | Janssen Pharmaceutica Nv | Ligandos de obtención de imágenes de tau por PET |
| CN106496061B (zh) * | 2016-10-20 | 2018-06-05 | 湘潭大学 | 一种萃取分离酰化反应液中乙酰精胺的方法 |
| AR112027A1 (es) * | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
| US10323289B2 (en) * | 2017-06-26 | 2019-06-18 | Institut Pasteur | Treatments to eliminate HIV reservoirs and reduce viral load |
| WO2019045655A1 (en) | 2017-08-29 | 2019-03-07 | Chulabhorn Foundation | DERIVATIVES AND COMPOSITION OF QUINOLINE AND NAPHTHYRIDINE |
| US20200039989A1 (en) * | 2018-03-01 | 2020-02-06 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of dyrk/clk and uses thereof |
| WO2019186277A1 (en) | 2018-03-28 | 2019-10-03 | Institut Pasteur | Ultrasensitive hiv-1 p24 detection assay |
| EP3594205A1 (en) | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-aryl derivatives for treating a rna virus infection |
| WO2020128033A1 (en) | 2018-12-20 | 2020-06-25 | Institut Pasteur | Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells |
| EP3669874A1 (en) * | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of cancer |
| EP3669873A1 (en) * | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
| KR20220009442A (ko) | 2019-05-15 | 2022-01-24 | 아론바이오 리미티드 | 암 치료, 케모카인 활성 억제 및/또는 세포사 유도를 위한 소분자 |
| EP3858815A1 (en) | 2020-01-31 | 2021-08-04 | Abivax | Co-crystals and salts of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine |
| EP4096640A1 (en) | 2020-01-31 | 2022-12-07 | Abivax | Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine |
| EP3858336A1 (en) | 2020-01-31 | 2021-08-04 | Abivax | Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine |
| JP2023521564A (ja) | 2020-03-20 | 2023-05-25 | アビバックス | コロナウイルス科ウイルス感染症を処置又は予防する為の化合物及びコロナウイルス科ウイルス感染症の発生を評価する方法及び使用方法 |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| EP4175719A1 (en) | 2020-07-02 | 2023-05-10 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| EP4298099A1 (en) | 2021-02-25 | 2024-01-03 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| EP4063351A1 (en) | 2021-03-26 | 2022-09-28 | Abivax | Preparation method of quinoline derivative compounds |
| EP4349831A1 (en) | 2021-05-27 | 2024-04-10 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Quinolinamine compound, preparation method therefor and application thereof in pharmaceuticals |
| KR20230072900A (ko) | 2021-11-18 | 2023-05-25 | 동우 화인켐 주식회사 | 마이크로 led 구조체 및 이의 제조방법 |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
| WO2023138657A1 (zh) * | 2022-01-24 | 2023-07-27 | 江苏恒瑞医药股份有限公司 | 喹啉胺类化合物、其制备方法及其在医药上的应用 |
| EP4215196A1 (en) | 2022-01-24 | 2023-07-26 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR400973A (fr) | 1909-03-19 | 1909-08-13 | Jean Victor Massillon | Nouveau sertisseur à main pour la fabrication des cartouches |
| GB585362A (en) | 1944-08-31 | 1947-02-05 | Francis Henry Swinden Curd | New heterocyclic compounds |
| BE486034A (pt) | 1947-11-28 | |||
| DE958647C (de) | 1952-12-28 | 1957-02-21 | Hoechst Ag | Verfahren zur Herstellung von 7-Amino-2-oxy-4-methyl-chinolinen |
| FR2387229A1 (fr) | 1977-04-13 | 1978-11-10 | Anvar | Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant |
| FR2436786A1 (fr) | 1978-09-21 | 1980-04-18 | Anvar | Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments |
| FR2627493B1 (fr) * | 1988-02-23 | 1991-10-31 | Sanofi Sa | Procede de preparation de derives d'isoquinoleine |
| FR2645861A1 (fr) * | 1989-04-17 | 1990-10-19 | Inst Nat Sante Rech Med | Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| EP1165064B1 (en) * | 1999-04-05 | 2004-02-25 | City of Hope | Novel inhibitors of formation of advanced glycation endproducts (age's) |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| DE10013318A1 (de) * | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Formulierung enthaltend Chinoxalinderivate |
| EP1353907A2 (en) | 2001-01-22 | 2003-10-22 | Memory Pharmaceutical Corporation | Phosphodiesterase 4 inhibitors |
| ES2355472T3 (es) | 2002-05-22 | 2011-03-28 | Amgen Inc. | Derivados de aminopirimidina para su uso como ligandos del receptor vaniloide para el tratamiento del dolor. |
| AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| CA2492907A1 (en) * | 2002-07-19 | 2004-01-29 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs |
| FR2849474B3 (fr) | 2002-12-27 | 2004-12-03 | Olivier Jean Noel Juin | Installation de transformation de l'energie cinetique d'un fluide en energie electrique |
| WO2004078731A1 (fr) | 2003-03-06 | 2004-09-16 | 'chemical Diversity Research Institute', Ltd. | Acides quinoline-carboxyliques et leurs derives et bibliotheque focalisee |
| EP1601357A4 (en) * | 2003-03-10 | 2007-10-03 | Schering Corp | HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS |
| FR2859475A1 (fr) | 2003-09-04 | 2005-03-11 | Centre Nat Rech Scient | Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
| FR2859474B1 (fr) | 2003-09-04 | 2006-01-13 | Centre Nat Rech Scient | Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
| JP2007509059A (ja) * | 2003-10-16 | 2007-04-12 | カイロン コーポレイション | 癌の処置のためのＲａｆキナーゼのインヒビターとしての、２，６−二置換キナゾリン、キノキサリン、キノリンおよびイソキノリン |
| BRPI0416692A (pt) * | 2003-11-19 | 2007-01-30 | Array Biopharma Inc | inibidores heterocìclicos de mek e métodos de emprego destes |
| WO2006051311A1 (en) * | 2004-11-12 | 2006-05-18 | Galapagos Nv | Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes |
| EP1853265B1 (en) | 2005-01-28 | 2016-01-27 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Farnesyltransferase inhibitors for use in the treatment of laminopathies, cellular aging and atherosclerosis |
| WO2007000876A1 (ja) * | 2005-06-29 | 2007-01-04 | Adeka Corporation | 樹脂添加剤組成物及びその樹脂組成物 |
| FR2903312B1 (fr) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament |
| WO2008008234A1 (en) | 2006-07-07 | 2008-01-17 | Targegen, Inc. | 2-amino-5-substituted pyrimidine inhibitors |
| AU2008206045A1 (en) * | 2007-01-19 | 2008-07-24 | Ardea Biosciences, Inc. | Inhibitors of MEK |
| FR2912745A1 (fr) * | 2007-02-19 | 2008-08-22 | Centre Nat Rech Scient | Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant |
| CA2681481A1 (en) * | 2007-03-16 | 2008-09-25 | Mount Sinai School Of Medicine | Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction |
| US8222634B2 (en) * | 2007-05-17 | 2012-07-17 | Lg Chem, Ltd. | Anthracene derivatives and organic electronic device using the same |
| UY31272A1 (es) * | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| MX2010001576A (es) | 2007-08-15 | 2010-09-14 | Memory Pharm Corp | Compuestos 3´sustituidos que tienen afinidad con el receptor 5-hidroxitriptamina 6 (5-ht6). |
| WO2009029617A1 (en) * | 2007-08-27 | 2009-03-05 | Kalypsys, Inc. | Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors |
| KR100974562B1 (ko) * | 2007-12-31 | 2010-08-06 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 발광재료로서 채용하고있는 유기 발광 소자 |
| FR2926297B1 (fr) | 2008-01-10 | 2013-03-08 | Centre Nat Rech Scient | Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage. |
| WO2010076339A1 (en) * | 2009-01-05 | 2010-07-08 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants |
| CN102272090A (zh) * | 2009-01-06 | 2011-12-07 | 帝斯曼知识产权资产管理有限公司 | 制备白藜芦醇中间体的方法 |
| CA2744670C (en) * | 2009-01-06 | 2018-05-15 | Ziad Mallat | A b cell depleting agent for the treatment of atherosclerosis |
| MX2019008390A (es) * | 2009-06-12 | 2019-09-09 | Abivax | Compuestos utiles para tratar cancer. |
| EP2266972A1 (en) | 2009-06-12 | 2010-12-29 | Splicos | New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies |
| MX359575B (es) | 2009-06-12 | 2018-10-03 | Abivax | Compuestos utiles para tratar sida. |
| US8962583B2 (en) | 2009-06-25 | 2015-02-24 | The Brigham And Women's Hospital, Inc. | Treatment of inflammatory diseases using miR-124 |
| EP2465502A1 (en) * | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
| WO2014055944A1 (en) | 2012-10-04 | 2014-04-10 | Oyagen, Inc. | Small molecules as anti-hiv agents that disrupt vif self-association and methods of use thereof |
| EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| JP2015120566A (ja) * | 2013-12-20 | 2015-07-02 | ニチユ三菱フォークリフト株式会社 | 荷役車両 |
-
2010
- 2010-06-14 MX MX2016003039A patent/MX359575B/es unknown
- 2010-06-14 KR KR1020177021820A patent/KR101863021B1/ko active IP Right Grant
- 2010-06-14 CA CA2764026A patent/CA2764026C/en active Active
- 2010-06-14 CU CUP2011000229A patent/CU24124B1/es active IP Right Grant
- 2010-06-14 CA CA3070823A patent/CA3070823C/en active Active
- 2010-06-14 HR HRP20230143TT patent/HRP20230143T1/hr unknown
- 2010-06-14 PL PL10728369.9T patent/PL2440546T3/pl unknown
- 2010-06-14 WO PCT/IB2010/052652 patent/WO2010143170A2/en active Application Filing
- 2010-06-14 ES ES10728368T patent/ES2736198T3/es active Active
- 2010-06-14 KR KR1020197004605A patent/KR102016890B1/ko active IP Right Grant
- 2010-06-14 PT PT107283699T patent/PT2440546T/pt unknown
- 2010-06-14 KR KR1020187025624A patent/KR101973348B1/ko active IP Right Grant
- 2010-06-14 FI FIEP10728369.9T patent/FI2440546T3/fi active
- 2010-06-14 ES ES10757474T patent/ES2938532T3/es active Active
- 2010-06-14 TR TR2019/10781T patent/TR201910781T4/tr unknown
- 2010-06-14 CA CA2965791A patent/CA2965791C/en active Active
- 2010-06-14 ES ES10728369T patent/ES2940885T3/es active Active
- 2010-06-14 MX MX2011013119A patent/MX353776B/es active IP Right Grant
- 2010-06-14 CU CUP2015000024A patent/CU24245B1/es unknown
- 2010-06-14 CN CN201410106644.9A patent/CN103948594B/zh active Active
- 2010-06-14 KR KR1020127000914A patent/KR20120051643A/ko active Search and Examination
- 2010-06-14 PT PT107574741T patent/PT2440547T/pt unknown
- 2010-06-14 JP JP2012514587A patent/JP5905385B2/ja active Active
- 2010-06-14 CU CU2011000228A patent/CU24461B1/es unknown
- 2010-06-14 KR KR1020197004608A patent/KR102016893B1/ko active IP Right Grant
- 2010-06-14 KR KR1020177031675A patent/KR101897221B1/ko active IP Right Grant
- 2010-06-14 BR BRPI1010772A patent/BRPI1010772B8/pt active IP Right Grant
- 2010-06-14 HU HUE10728368A patent/HUE045548T2/hu unknown
- 2010-06-14 DK DK10728369.9T patent/DK2440546T3/da active
- 2010-06-14 JP JP2012514586A patent/JP5826745B2/ja active Active
- 2010-06-14 AU AU2010258295A patent/AU2010258295B2/en active Active
- 2010-06-14 CN CN201710122014.4A patent/CN106905232B/zh active Active
- 2010-06-14 EP EP19157824.4A patent/EP3521283B1/en active Active
- 2010-06-14 KR KR1020187025625A patent/KR101982462B1/ko active IP Right Grant
- 2010-06-14 AU AU2010258294A patent/AU2010258294B2/en active Active
- 2010-06-14 CN CN202110307700.5A patent/CN113004249A/zh active Pending
- 2010-06-14 PT PT10728368T patent/PT2440545T/pt unknown
- 2010-06-14 KR KR1020197004606A patent/KR102016891B1/ko active IP Right Grant
- 2010-06-14 MX MX2011013120A patent/MX338823B/es active IP Right Grant
- 2010-06-14 JP JP2012514585A patent/JP6041671B2/ja active Active
- 2010-06-14 EP EP19157827.7A patent/EP3517534B1/en active Active
- 2010-06-14 MX MX2016007353A patent/MX367601B/es unknown
- 2010-06-14 CN CN201910120757.7A patent/CN109776496B/zh active Active
- 2010-06-14 AU AU2010258214A patent/AU2010258214B2/en active Active
- 2010-06-14 MX MX2015016293A patent/MX364989B/es unknown
- 2010-06-14 EP EP10728369.9A patent/EP2440546B1/en active Active
- 2010-06-14 MX MX2011013122A patent/MX340095B/es active IP Right Grant
- 2010-06-14 EP EP10728368.1A patent/EP2440545B1/en active Active
- 2010-06-14 CU CU2011000230A patent/CU24093B1/es active IP Right Grant
- 2010-06-14 BR BRPI1012892A patent/BRPI1012892B8/pt active IP Right Grant
- 2010-06-14 KR KR1020197004607A patent/KR102016892B1/ko active IP Right Grant
- 2010-06-14 FI FIEP10757474.1T patent/FI2440547T3/fi active
- 2010-06-14 HR HRP20230248TT patent/HRP20230248T1/hr unknown
- 2010-06-14 PL PL10757474.1T patent/PL2440547T3/pl unknown
- 2010-06-14 CN CN201080032055.0A patent/CN102596935B/zh active Active
- 2010-06-14 US US13/377,760 patent/US9145367B2/en active Active
- 2010-06-14 CN CN201710158473.8A patent/CN106928205B/zh active Active
- 2010-06-14 BR BRPI1010768A patent/BRPI1010768C8/pt active IP Right Grant
- 2010-06-14 US US13/377,745 patent/US20120277230A1/en not_active Abandoned
- 2010-06-14 BR BR122019013686-6A patent/BR122019013686B1/pt active IP Right Grant
- 2010-06-14 MX MX2015016291A patent/MX364279B/es unknown
- 2010-06-14 HU HUE10757474A patent/HUE061262T2/hu unknown
- 2010-06-14 SI SI201032127T patent/SI2440547T1/sl unknown
- 2010-06-14 RU RU2011149571/04A patent/RU2567752C2/ru active
- 2010-06-14 KR KR1020127000915A patent/KR101789275B1/ko active IP Right Grant
- 2010-06-14 CN CN201080032045.7A patent/CN102625804B/zh active Active
- 2010-06-14 DK DK10728368.1T patent/DK2440545T3/da active
- 2010-06-14 CN CN201510023124.6A patent/CN104844570B/zh active Active
- 2010-06-14 MX MX2015016292A patent/MX364280B/es unknown
- 2010-06-14 KR KR1020187025626A patent/KR101982463B1/ko active IP Right Grant
- 2010-06-14 US US13/377,753 patent/US20120329796A1/en not_active Abandoned
- 2010-06-14 PL PL10728368T patent/PL2440545T3/pl unknown
- 2010-06-14 CA CA2764024A patent/CA2764024C/en active Active
- 2010-06-14 WO PCT/IB2010/052650 patent/WO2010143168A2/en active Application Filing
- 2010-06-14 CN CN201510023109.1A patent/CN104844510B/zh active Active
- 2010-06-14 DK DK10757474.1T patent/DK2440547T3/da active
- 2010-06-14 CA CA2764027A patent/CA2764027C/en active Active
- 2010-06-14 LT LTEPPCT/IB2010/052651T patent/LT2440547T/lt unknown
- 2010-06-14 CN CN201510020820.1A patent/CN104945378B/zh active Active
- 2010-06-14 KR KR1020127000916A patent/KR101769616B1/ko active IP Right Grant
- 2010-06-14 EP EP10757474.1A patent/EP2440547B1/en active Active
- 2010-06-14 CN CN201510021597.2A patent/CN104945379B/zh active Active
- 2010-06-14 EP EP22193611.5A patent/EP4198022A1/en active Pending
- 2010-06-14 BR BR122019013687A patent/BR122019013687B1/pt active IP Right Grant
- 2010-06-14 KR KR1020197004604A patent/KR102016889B1/ko active IP Right Grant
- 2010-06-14 CN CN201080032036.8A patent/CN102574835B/zh active Active
- 2010-06-14 WO PCT/IB2010/052651 patent/WO2010143169A2/en active Application Filing
- 2010-06-14 MX MX2015016290A patent/MX364282B/es unknown
- 2010-06-14 CN CN201710158474.2A patent/CN106928194B/zh active Active
- 2010-06-14 KR KR1020187025623A patent/KR101982461B1/ko active IP Right Grant
-
2011
- 2011-12-08 ZA ZA2011/09032A patent/ZA201109032B/en unknown
- 2011-12-08 ZA ZA2011/09031A patent/ZA201109031B/en unknown
-
2013
- 2013-01-11 HK HK13100514.2A patent/HK1173153A1/xx unknown
- 2013-01-17 HK HK16101080.1A patent/HK1213247A1/zh unknown
- 2013-01-17 HK HK16101079.4A patent/HK1213246A1/zh unknown
- 2013-01-17 HK HK16100761.9A patent/HK1212702A1/zh unknown
- 2013-01-17 HK HK13100736.4A patent/HK1173726A1/zh unknown
- 2013-01-17 HK HK13100731.9A patent/HK1173447A1/zh unknown
- 2013-01-17 HK HK16101060.5A patent/HK1212990A1/zh unknown
- 2013-11-22 US US14/087,762 patent/US9108919B2/en active Active
-
2014
- 2014-04-18 US US14/256,334 patent/US9908869B2/en active Active
-
2015
- 2015-01-30 HK HK15101062.4A patent/HK1200363A1/xx unknown
- 2015-04-27 JP JP2015090437A patent/JP2015155453A/ja active Pending
- 2015-06-15 JP JP2015120568A patent/JP6158251B2/ja active Active
- 2015-06-15 JP JP2015120567A patent/JP6158250B2/ja active Active
- 2015-06-15 JP JP2015120566A patent/JP2015187150A/ja not_active Withdrawn
- 2015-07-01 US US14/789,149 patent/US9637475B2/en active Active
- 2015-07-01 US US14/789,250 patent/US10017498B2/en active Active
-
2019
- 2019-10-18 JP JP2019191500A patent/JP7042245B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1012892A2 (pt) | composto, e, composição farmacêutica. | |
| BRPI0906962A2 (pt) | Composto, e, composição farmacêutica | |
| BRPI0906556A2 (pt) | Composto, e, composição farmacêutica | |
| BRPI0910503A2 (pt) | compostos, composições farmacêuticas e respectivos usos. | |
| BRPI1010301A2 (pt) | composição. | |
| BRPI1007018A2 (pt) | composto, composição farmacêutica, e , uso de um composto. | |
| BRPI0815773A2 (pt) | composto, e, medicamento. | |
| BR112012004335A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
| BRPI1008906A2 (pt) | composto, composição farmacêutica, e, uso de um composto. | |
| BRPI0917681A2 (pt) | Composto, e, composição farmacêutica | |
| BRPI0812354A2 (pt) | Composição farmacêutica não-aquosa. | |
| BRPI1009372A2 (pt) | compostos, composição farmacêutica e respectivos usos | |
| BRPI1016190A2 (pt) | compostos farmacêuticos. | |
| BR112012003800A2 (pt) | composição, peptídeo, e formulação farmacêutica. | |
| BR112012000831A2 (pt) | compostos, composições farmacêuticas e métodos relacionados | |
| BR112013019327A2 (pt) | composto, e, composição. | |
| BRPI0807078A2 (pt) | Composto, e, formulação farmacêutica | |
| BRPI0918637A2 (pt) | composição antimicrobiana. | |
| BRPI1011460A2 (pt) | Composição desinfetante. | |
| BRPI1009757A2 (pt) | composto, composição farmacêutica, e , uso de um composto. | |
| IT1396487B1 (it) | Convogliatore. | |
| DK2442870T3 (da) | Pyrazinooxazepin-derivater. | |
| BRPI0912118A2 (pt) | composto, composição farmacêutica, e, intermediário sintético | |
| BRPI0914182A2 (pt) | composto, e, composição farmacêutica | |
| BRPI0922286A2 (pt) | composto de quinolona e composição farmacêutica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) , INSTITUT CURIE (FR) , UNIVERSITE MONTPELLIER 2 (FR) , ABIVAX (FR) Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/10/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/06/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |